Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Non-Current Liabilities (2023 - 2025)

Eton Pharmaceuticals' Total Non-Current Liabilities history spans 3 years, with the latest figure at $77.4 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $77.4 million; the TTM value through Sep 2025 reached $77.4 million, changed N/A, while the annual FY2024 figure was $49.9 million, 206.62% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $77.4 million at Eton Pharmaceuticals, up from $73.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $77.4 million in Q3 2025 and bottomed at $16.3 million in Q4 2023.
  • The 3-year median for Total Non-Current Liabilities is $55.4 million (2025), against an average of $54.5 million.
  • The largest YoY upside for Total Non-Current Liabilities was 206.62% in 2024 against a maximum downside of 206.62% in 2024.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $16.3 million in 2023, then skyrocketed by 206.62% to $49.9 million in 2024, then soared by 55.3% to $77.4 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Total Non-Current Liabilities are $77.4 million (Q3 2025), $73.4 million (Q2 2025), and $55.4 million (Q1 2025).